China's Delays In Approving Clinical Trials, Poor IPR Block Access To Innovative Drugs - EU Chamber Of Commerce
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's lengthy process in reviewing clinical trial applications, unpredictable schedule for updating the national catalog of reimbursable drugs, and lax protection of intellectual property rights are all blocking access for most Chinese citizens to the latest innovative medicines developed worldwide, according to a leader in the European Union Chamber of Commerce in China